Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

2 recruiting4 with results

Enrollment Performance

Analytics

N/A
9(75.0%)
Phase 2
1(8.3%)
Phase 1
1(8.3%)
Phase 4
1(8.3%)
12Total
N/A(9)
Phase 2(1)
Phase 1(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT07189286Not ApplicableRecruiting

Preserving Ability Through Virtual Exercise (PAVE)

Role: collaborator

NCT06975423Not ApplicableRecruiting

Walking Sensation Study

Role: collaborator

NCT05666310Phase 4Active Not Recruiting

Muscle Impact of Treating Osteoporosis

Role: collaborator

NCT06191549Not ApplicableActive Not Recruiting

Brain Stimulation Enhance Post-stroke Walking Survivors and Healthy Adults

Role: collaborator

NCT04742777Phase 2Completed

Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]

Role: collaborator

NCT05766423Not ApplicableCompleted

Phenotyping Adherence Through Technology-Enabled Reports and Navigation

Role: collaborator

NCT04900272Not ApplicableCompleted

Intelligent Personal Assistant for Managing Depression in Homebound Older Adults

Role: collaborator

NCT04007523Not ApplicableCompleted

Recommendations and Alerting for Delirium Alleviation in Real-Time (RADAR)

Role: collaborator

NCT04440449Not ApplicableCompleted

Effect of Behavioral Lifestyle Intervention on Frailty in Older Adults With Diabetes

Role: collaborator

NCT03993574Not ApplicableUnknown

Feasibility of a Stroke Specific Self-management Program

Role: collaborator

NCT04482712Phase 1Withdrawn

Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS

Role: collaborator

NCT02844478Not ApplicableCompleted

Stress-Busting Program and QoL, Bio-markers of Immunity/Stress and Cellular Aging

Role: collaborator

All 12 trials loaded